Publications

Author

Henrik Vitus Bering Laursen

Here you will find a list of my publications, most of which are as a first author.

Not included here are:

Mainly Epidemiology

Critique of Health economic model assumptions using real-world data

Title Summary
Health economic model assumptions of pharmaceutical treatment paths compared with real-world evidence for patients with type 2 diabetes: A nationwide cohort study Using registry cohort from a previous study, we examined treatment regimen and time to insulin, by starting drug, and compared the findings with assumptions used in health economic models.

Figure 2: The plot for the Aalen-Johansen cumulative incidence function with 95% confidence intervals. Stratified by inclusion period. Truncated at 3 years for better comparability.

Nationwide cohort of Danish people with type 2 diabetes - what are the treatment patterns?

Title Summary
Trends in anti-hyperglycaemic drug usage among Danish type 2 diabetes patients on second-line treatment and beyond: A nationwide cohort study Creating a nationwide registry cohort of Danish people with T2D on newer antidiabetic drugs (SGLT2, GLP1, DPP4), and following drug utilization and treatment patterns.

Figure 3: Depicted here are the proportions of each drug class at each treatment stage for the cohort, i.e. the first to the sixth introduced drug for each individual patient, over time. Omitted bars in 2012 are due to insufficient or lacking data. MET = metformin, SU = sulfonylurea, DPP4 = dipeptidyl peptidase-4 inhibitors, GLP1 = glucagon-like peptide-1 receptor agonists, SGLT2 = sodium glucose co-transporter-2 inhibitor, TZD = thiazolidinedions, AGI = alpha-glucosidase inhibitor, INS = insulin, METandDPP4 = metformin and DPP4 combination, OTHERS = all other anti-hyperglycaemic drugs.

Systematic reviews

Rigorously checking the quality of real-world quality improvement

Title Summary
Can quality improvement improve the quality of care? A systematic review of reported effects and methodological rigor in plan-do-study-act projects Systematic review of 120 Quality Improvement studies. A comparison of ideal versus real-world Plan-Do-Study-Act usage in quality improvement practice.

a) Bar-chart depicting how often the four key features were used across the projects. b) Bar-chart depicting the number of projects, which had used zero to four key features

Going through cost-effectiveness models comparing GLP1 and SGLT2 for treatment of type 2 diabetes

Title Summary
A Systematic Review of Cost-Effectiveness Studies of Newer Non-Insulin Antidiabetic Drugs: Trends in Decision-Analytical Models for Modelling of Type 2 Diabetes Mellitus Systematic review of 50 cost-effectiveness analyses using decision-analytical modelling. Methodological critique of state of the art decision-analytical models, uncovering novel insights.

Fig. 1 Flow-chart for study selection, adapted from the PRISMA-guidelines for the reporting systematic reviews [32]. DAM decision-analytical model, nNIAD Non-insulin antidiabetic drugs

Risk of diabetic ketoacidosis after GLP1 or SGLT2

Title Summary
Sodium Glucose Cotransporter-2 Inhibitor Treatment and the Risk of Diabetic Ketoacidosis in Denmark: A Retrospective Cohort Study of Five Years of Use Conducted everything from data extraction to making a publication ready manuscript, risk of diabetic ketoacidosis. The study highlights connection between SGLT2s and diabetic ketoacidosis.

Diabetes and amputations

Title Summary
Twenty years with diabetes and amputations: a retrospective population-based cohort study Setting up a case-control study using registry data. Learned a lot of basic data cleaning, wrangling, and statistical programming making for this paper